Supplement × Prescription·Evidence index
PubMed indexes 8 records that name Amoxicillin and Saccharomyces Boulardii together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Amoxicillin and Saccharomyces Boulardii. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“Supplementing vonoprazan-amoxicillin dual therapy with S. boulardii significantly increases H. pylori eradication rates and reduces adverse events, offering an effective and simple rescue treatment unaffected by previous treatment failures.”
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“Addition of S. boulardii to VA-dual for 10 days is as effective as the 14-days bismuth-based quadruple regimen while ensuring fewer adverse events and lesser cost. This regimen is particularly suitable for low-BSA patients or non-smokers.”
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“S. boulardii treatment can mitigate some antibiotic-induced microbiota changes (dysbiosis) and can also reduce antibiotic-associated diarrhea.”
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“Saccharomyces boulardii (500 mg/day) did not prevent diarrhea related to amoxicillin.”
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“boulardii comes in various formulations and dosages, warranting further exploration into the optimal dosage for supplementation in rescue therapy. Additionally, larger, randomized, double-blinded controlled trials are warranted to confirm these promising results.”
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“Conclusions Altogether, our findings suggest that coadministration or concurrent use of S. boulardii probiotic and amoxicillin would not likely alter the efficacy of amoxicillin therapy.”
Names both Amoxicillin and Saccharomyces Boulardii in its title.
“Adding probiotics, particularly S. boulardii or multi-strain combinations, to BQT significantly improves eradication efficacy and decreases treatment-related adverse events. PBQT represents a pragmatic optimization of current first-line regimens and supports its incorporation into clinical practice to improve H. pylori treatment outcomes.”
Names Amoxicillin and Saccharomyces Boulardii together in an interaction, co-administration, or pharmacokinetic context.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Amoxicillin, Saccharomyces Boulardii, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
